200
Participants
Start Date
June 25, 2019
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2025
DTG 50 mg OD with food
Dolutegravir 50 mg once daily with food plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy
DTG 50 mg BID
Dolutegravir 50 mg BID plus 2NRTIs in HIV/TB co-infected patients receiving RIF based anti-TB therapy.
RECRUITING
Klang Hospital, Bangkok
RECRUITING
Bhumibol Adulyadej Hospital, Bangkok
RECRUITING
Infectious Disease, Chulalongkorn University, Bangkok
RECRUITING
Chest Division, Faculty of Medicine, Chulalongkorn University, Bangkok
RECRUITING
HIV-NAT, Thai Red Cross - AIDS Research Centre, Bangkok
RECRUITING
Infectious Disease Taksin Hospital, Bangkok
RECRUITING
Bamrasnaradura Infectious Diseases Institute, Nonthaburi
RECRUITING
Infectious Disease Chonburi Hospital, Chon Buri
RECRUITING
Infectious Disease Chiangrai Prachanukroh Hospital, Chiang Rai
RECRUITING
Infectious Disease Buddhachinaraj Phitsanulok Hospital, Phitsanulok
Chest Division, Chulalongkorn University
UNKNOWN
Infectious Disease, Chulalongkorn University
UNKNOWN
Bamrasnaradura Infectious Diseases Institute
OTHER_GOV
Bhumibol Adulyadej Hospital
OTHER
Infectious Disease Taksin Hospital
UNKNOWN
Klang Hospital
UNKNOWN
Infectious Disease Chiangrai Prachanukroh Hospital
UNKNOWN
Infectious Disease Chonburi Hospital
UNKNOWN
Infectious Disease Buddhachinaraj Phitsanulok Hospital
UNKNOWN
Radboud University Medical Center
OTHER
Ministry of Health, Thailand
OTHER_GOV
The HIV Netherlands Australia Thailand Research Collaboration
OTHER